According to the 2025 WHO classification, SCO represents one of four recognized subtypes of posterior pituitary tumors derived from pituicytes, unified by diffuse nuclear TTF-1 expression and a shared origin from the ventral neuroectoderm. The gene discussed is TTF1; the disease is posterior pituitary gland neoplasm.